두경부 편평상피암(HNSCC) 시장 - 세계 산업 규모, 점유율, 동향, 기회, 예측, 유형별, 치료별, 투여 경로별, 최종사용자별, 지역별 부문, 경쟁(2020-2030년)
Head and Neck Squamous Cell Carcinoma Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By Treatment, By Route of Administration, By End-user, By Region and Competition, 2020-2030F
상품코드:1691735
리서치사:TechSci Research
발행일:2025년 03월
페이지 정보:영문 184 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
한글목차
두경부 편평상피암(HNSCC) 세계 시장 규모는 2024년 24억 1,000만 달러로 평가되었고, 예측 기간 동안 39억 4,000만 달러에 달할 것으로 예상되며, 2030년까지 8.52%의 연평균 복합 성장률(CAGR)을 나타낼 것으로 예상됩니다.
두경부 편평상피암(HNSCC) 세계 시장은 이 질환의 유병률 증가와 치료법의 발전으로 인해 크게 성장하고 있습니다. 담배와 알코올 섭취, 인유두종 바이러스(HPV) 감염, 유전적 소인 등의 요인으로 인해 HNSCC 환자 수가 증가함에 따라 혁신적인 치료법에 대한 수요가 증가하고 있습니다. 제약회사와 생명공학 기업들은 생존율을 향상시키기 위해 면역관문억제제, 단클론 항체 등 새로운 표적 치료제를 개발하기 위한 연구 노력을 강화하고 있습니다. 저침습 수술 및 로봇 보조 수술의 도입으로 치료 정확도가 향상되어 환자의 예후를 개선하고 회복 시간을 단축하는 데 기여하고 있습니다.
시장 개요
예측 기간
2026-2030년
시장 규모 : 2024년
24억 1,000만 달러
시장 규모 : 2030년
39억 4,000만 달러
CAGR : 2025-2030년
8.52%
급성장 부문
면역요법
최대 시장
북미
맞춤의료와 바이오마커 중심의 치료 접근법에 중점을 둔 연구개발 투자와 임상시험이 치료의 전망을 크게 바꾸고 있습니다. 면역요법, 특히 PD-1/PD-L1 억제제는 암세포에 대한 면역체계의 반응을 강화하는 능력으로 인해 진행성 HNSCC의 선호되는 치료 옵션으로 각광받고 있습니다. 화학요법, 방사선요법, 면역요법을 통합한 병용요법의 개발은 환자의 예후 개선에 유망한 결과를 보이고 있습니다. 액체생검과 AI를 활용한 진단을 통한 조기 발견으로의 전환은 환자 관리의 간소화와 치료 선택의 최적화를 가져와 궁극적으로 생존율 향상으로 이어질 것으로 기대됩니다.
이 시장은 또한 표적 치료제의 높은 비용, 질병의 조기 발견에 대한 제한된 인식, 서로 다른 의료 환경 간의 치료 접근성 격차 등의 문제를 겪고 있습니다. 기존 치료제에 대한 내성 및 특정 치료제의 부작용은 환자의 최적의 치료 결과를 달성하는 데 있어 여전히 중요한 장애물이 되고 있습니다. 이러한 도전에도 불구하고, 임상연구의 확대, 암 연구를 지원하는 정부 이니셔티브, 암 치료에서 AI와 정밀의료의 통합에 대한 관심이 높아지는 등 기회는 존재합니다. 바이오 제약사, 규제 당국, 연구 기관의 전략적 협력은 HNSCC 치료 환경의 미래를 형성하는 데 중요한 역할을 할 것이며, 혁신적인 치료법이 더 많은 환자 집단에 도달할 수 있도록 보장할 것입니다.
시장 성장 촉진요인
두경부 편평상피암의 유병률 증가 추세
주요 시장 이슈
조기 발견과 검진의 한계
주요 시장 동향
표적 치료의 발전
목차
제1장 개요
제2장 조사 방법
제3장 주요 요약
제4장 세계의 두경부 편평상피암(HNSCC) 시장 전망
시장 규모와 예측
금액별
시장 점유율과 예측
유형별(침샘, 구강 및 구인두, 비강 및 부비강, 비인두, 후두, 하인두)
투여 경로별(정맥내, 경구, 기타)
치료별(방사선 요법, 화학요법, 면역치료)
최종사용자별(병원 및 진료소, 외래 진료 센터, 기타)
지역별
기업별(2024년)
시장 맵
유형별
투여 경로별
치료별
최종사용자별
지역별
제5장 아시아태평양의 두경부 편평상피암(HNSCC) 시장 전망
시장 규모와 예측
금액별
시장 점유율과 예측
유형별
투여 경로별
치료별
최종사용자별
국가별
아시아태평양 : 국가별 분석
중국
인도
호주
일본
한국
제6장 유럽의 두경부 편평상피암(HNSCC) 시장 전망
시장 규모와 예측
시장 점유율과 예측
유럽 : 국가별 분석
독일
스페인
이탈리아
영국
제7장 북미의 두경부 편평상피암(HNSCC) 시장 전망
시장 규모와 예측
시장 점유율과 예측
북미 : 국가별 분석
멕시코
캐나다
제8장 남미의 두경부 편평상피암(HNSCC) 시장 전망
시장 규모와 예측
시장 점유율과 예측
남미 : 국가별 분석
아르헨티나
콜롬비아
제9장 중동 및 아프리카의 두경부 편평상피암(HNSCC) 시장 전망
시장 규모와 예측
시장 점유율과 예측
중동 및 아프리카 : 국가별 분석
사우디아라비아
아랍에미리트(UAE)
제10장 시장 역학
성장 촉진요인
과제
제11장 시장 동향과 발전
최근 동향
제품 출시
인수합병(M&A)
제12장 세계의 두경부 편평상피암(HNSCC) 시장 : SWOT 분석
제13장 Porter의 Five Forces 분석
업계내 경쟁
신규 참여 가능성
공급업체의 힘
고객의 힘
대체품의 위협
제14장 경쟁 구도
F. Hoffmann-La Roche Ltd.
Boehringer Ingelheim International GmbH.
GSK plc
Novartis AG
Bayer AG
Merck & Co., Inc.
AstraZeneca Plc
Eli Lilly and Company
Cipla Inc.
Sanofi
제15장 전략적 제안
제16장 리서치사에 대해 & 면책사항
LSH
영문 목차
영문목차
Global Head and Neck Squamous Cell Carcinoma Market was valued at USD 2.41 Billion in 2024 and is expected to reach USD 3.94 Billion in the forecast period with a CAGR of 8.52% through 2030. The Global Head and Neck Squamous Cell Carcinoma (HNSCC) Market is experiencing significant expansion due to the increasing prevalence of the disease and advancements in treatment modalities. Rising cases of HNSCC, largely driven by factors such as tobacco and alcohol consumption, human papillomavirus (HPV) infections, and genetic predisposition, are fueling demand for innovative therapies. Pharmaceutical and biotechnology companies are intensifying research efforts to develop novel targeted therapies, including immune checkpoint inhibitors and monoclonal antibodies, to improve survival rates. The adoption of minimally invasive surgical techniques and robotic-assisted procedures is enhancing treatment precision, leading to better patient outcomes and reducing recovery time.
Market Overview
Forecast Period
2026-2030
Market Size 2024
USD 2.41 Billion
Market Size 2030
USD 3.94 Billion
CAGR 2025-2030
8.52%
Fastest Growing Segment
Immunotherapy
Largest Market
North America
R&D investments and clinical trials focusing on personalized medicine and biomarker-driven treatment approaches are transforming the therapeutic landscape. Immunotherapy, particularly PD-1/PD-L1 inhibitors, is gaining traction as a preferred treatment option for advanced HNSCC due to its ability to enhance the immune system's response against cancer cells. The development of combination therapies integrating chemotherapy, radiation, and immunotherapy is showing promising results in improving patient prognosis. The shift toward early detection through liquid biopsies and AI-driven diagnostics is expected to streamline patient management and optimize treatment selection, ultimately improving survival rates.
The market is also witnessing challenges, including the high cost of targeted therapies, limited awareness about early disease detection, and disparities in treatment accessibility across different healthcare settings. Resistance to existing therapies and adverse effects associated with certain treatments remain key hurdles in achieving optimal patient outcomes. Despite these challenges, opportunities exist in the form of expanding clinical research, government initiatives supporting cancer research, and an increasing focus on integrating AI and precision medicine in oncology. Strategic collaborations between biopharmaceutical firms, regulatory agencies, and research institutions will play a crucial role in shaping the future of the HNSCC treatment landscape, ensuring innovative therapies reach a broader patient population.
Key Market Drivers
Increasing Prevalence of Head and Neck Squamous Cell Carcinoma
The Global Head and Neck Squamous Cell Carcinoma (HNSCC) Market is experiencing significant growth, primarily due to the increasing prevalence of this devastating cancer worldwide. HNSCC has become a global health concern, affecting the mucous membranes of the head and neck, including the oral cavity, throat, and larynx. The surge in HNSCC cases is driven by several key factors, contributing to the expansion of the HNSCC market.
One prominent factor behind the rising prevalence of HNSCC is the widespread consumption of tobacco and alcohol. These well-established risk factors have significantly contributed to the growing incidence of the disease, particularly among individuals with long-term or heavy use. According to the National Cancer Institute, the rate of new cases of oral cavity and pharynx cancer was 11.5 per 100,000 men and women per year, with a death rate of 2.6 per 100,000 men and women per year, based on data from 2017 to 2021. The synergistic effects of tobacco and alcohol increase susceptibility to HNSCC, emphasizing the need for effective treatments and interventions.
Another critical contributor to the increasing prevalence of HNSCC is human papillomavirus (HPV) infection. HPV-associated HNSCC cases have been on the rise, with the virus identified as a major risk factor for oropharyngeal cancers, a subset of HNSCC. The Centers for Disease Control and Prevention (CDC) reports that HPV is thought to cause 60% to 70% of oropharyngeal cancers in the United States. This growing recognition has led to heightened awareness, early detection efforts, and research into novel treatment strategies.
Additionally, changing lifestyle patterns and dietary habits have contributed to the rising incidence of HNSCC. Factors such as poor nutrition, exposure to environmental carcinogens, and genetic predisposition play roles in the disease's prevalence. As HNSCC cases continue to increase globally, there is an urgent need to address this healthcare challenge effectively. This urgency has spurred research efforts, innovations in diagnostics, development of targeted therapies, and exploration of immunotherapeutic interventions, aiming to improve patient outcomes and reduce the global burden of HNSCC.
Key Market Challenges
Limited Early Detection and Screening
Limited early detection and screening capabilities represent a significant hurdle in the advancement of the Global Head and Neck Squamous Cell Carcinoma (HNSCC) Market. HNSCC is a complex and often aggressive form of cancer that affects various anatomical regions in the head and neck, including the oral cavity, pharynx, and larynx. The lack of effective early detection methods poses substantial challenges in managing this disease.
One of the primary reasons for the limited early detection of HNSCC is its asymptomatic nature in the initial stages. Unlike some other cancers that may manifest noticeable symptoms early on, HNSCC often develops silently, without obvious warning signs. This makes it difficult for both patients and healthcare providers to recognize the disease in its early, more treatable phases. By the time symptoms do appear, the cancer has often progressed to an advanced stage, reducing treatment options and compromising patient outcomes.
Moreover, HNSCC can occur in anatomical locations that are not easily visible or accessible during routine physical examinations. These cancers may develop deep within the throat or in the tonsils, making them less likely to be detected by routine check-ups. As a result, patients frequently present with advanced-stage HNSCC, requiring more aggressive treatments and experiencing a higher risk of recurrence.
Key Market Trends
Advances in Targeted Therapies
Advances in targeted therapies have emerged as a pivotal force propelling the growth of the Global Head and Neck Squamous Cell Carcinoma (HNSCC) Market. HNSCC is a complex and aggressive form of cancer that affects various regions within the head and neck, and traditional treatments often come with substantial side effects and limited efficacy. Targeted therapies have offered a more precise and effective approach to combating this disease.
One of the key advantages of targeted therapies in HNSCC treatment is their ability to specifically target cancer cells while sparing healthy tissue. These therapies are designed to interfere with specific molecular pathways or proteins that play a crucial role in tumor growth and progression. For instance, cetuximab, an EGFR inhibitor, has been approved for HNSCC treatment. By blocking the epidermal growth factor receptor, cetuximab can inhibit the uncontrolled growth of cancer cells.
The development of targeted therapies is closely tied to our increasing understanding of the molecular biology of HNSCC. Researchers have identified specific genetic mutations and biomarkers associated with HNSCC, allowing for the development of therapies that are tailored to the individual characteristics of each patient's tumor. This personalized approach not only enhances treatment efficacy but also minimizes side effects, leading to improved patient outcomes and a better quality of life during and after treatment.
Key Market Players
F. Hoffmann-La Roche Ltd.
Boehringer Ingelheim International GmbH.
GSK plc
Novartis AG
Bayer AG
Merck & Co., Inc.
AstraZeneca Plc
Eli Lilly and Company
Cipla Inc.
Sanofi
Report Scope:
In this report, the Global Head and Neck Squamous Cell Carcinoma Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Head and Neck Squamous Cell Carcinoma Market, By Type:
Salivary Gland
Oral and Oropharyngeal
Nasal Cavity & Paranasal Sinuses
Nasopharyngeal
Laryngeal
Hypo Pharyngeal
Head and Neck Squamous Cell Carcinoma Market, By Treatment:
Radiation
Chemotherapy
Immunotherapy
Head and Neck Squamous Cell Carcinoma Market, By Route of Administration:
Oral
Intravenous
Others
Head and Neck Squamous Cell Carcinoma Market, By End-user:
Hospitals & Clinics
Ambulatory Care Centers
Others
Head and Neck Squamous Cell Carcinoma Market, By Region:
North America
United States
Canada
Mexico
Europe
France
United Kingdom
Italy
Germany
Spain
Asia-Pacific
China
India
Japan
Australia
South Korea
South America
Brazil
Argentina
Colombia
Middle East & Africa
South Africa
Saudi Arabia
UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Head and Neck Squamous Cell Carcinoma Market.
Available Customizations:
Global Head and Neck Squamous Cell Carcinoma Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
Detailed analysis and profiling of additional market players (up to five).
Table of Contents
1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Global Head and Neck Squamous Cell Carcinoma Market Outlook
4.1. Market Size & Forecast
4.1.1. By Value
4.2. Market Share & Forecast
4.2.1. By Type (Salivary Gland, Oral and Oropharyngeal, Nasal Cavity & Paranasal Sinuses, Nasopharyngeal, Laryngeal, Hypo Pharyngeal)
4.2.2. By Route of Administration (Intravenous, Oral, Others)
4.2.3. By Treatment (Radiation, Chemotherapy, Immunotherapy)
4.2.4. By End-user (Hospitals & Clinics, Ambulatory Care Centers, Others)
4.2.5. By Region
4.2.6. By Company (2024)
4.3. Market Map
4.3.1. By Type
4.3.2. By Route of Administration
4.3.3. By Treatment
4.3.4. By End-user
4.3.5. By Region
5. Asia Pacific Head and Neck Squamous Cell Carcinoma Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Type
5.2.2. By Route of Administration
5.2.3. By Treatment
5.2.4. By End-user
5.2.5. By Country
5.3. Asia Pacific: Country Analysis
5.3.1. China Head and Neck Squamous Cell Carcinoma Market Outlook
5.3.1.1. Market Size & Forecast
5.3.1.1.1. By Value
5.3.1.2. Market Share & Forecast
5.3.1.2.1. By Type
5.3.1.2.2. By Route of Administration
5.3.1.2.3. By Treatment
5.3.1.2.4. By End-user
5.3.2. India Head and Neck Squamous Cell Carcinoma Market Outlook
5.3.2.1. Market Size & Forecast
5.3.2.1.1. By Value
5.3.2.2. Market Share & Forecast
5.3.2.2.1. By Type
5.3.2.2.2. By Route of Administration
5.3.2.2.3. By Treatment
5.3.2.2.4. By End-user
5.3.3. Australia Head and Neck Squamous Cell Carcinoma Market Outlook
5.3.3.1. Market Size & Forecast
5.3.3.1.1. By Value
5.3.3.2. Market Share & Forecast
5.3.3.2.1. By Type
5.3.3.2.2. By Route of Administration
5.3.3.2.3. By Treatment
5.3.3.2.4. By End-user
5.3.4. Japan Head and Neck Squamous Cell Carcinoma Market Outlook
5.3.4.1. Market Size & Forecast
5.3.4.1.1. By Value
5.3.4.2. Market Share & Forecast
5.3.4.2.1. By Type
5.3.4.2.2. By Route of Administration
5.3.4.2.3. By Treatment
5.3.4.2.4. By End-user
5.3.5. South Korea Head and Neck Squamous Cell Carcinoma Market Outlook
5.3.5.1. Market Size & Forecast
5.3.5.1.1. By Value
5.3.5.2. Market Share & Forecast
5.3.5.2.1. By Type
5.3.5.2.2. By Route of Administration
5.3.5.2.3. By Treatment
5.3.5.2.4. By End-user
6. Europe Head and Neck Squamous Cell Carcinoma Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Type
6.2.2. By Route of Administration
6.2.3. By Treatment
6.2.4. By End-user
6.2.5. By Country
6.3. Europe: Country Analysis
6.3.1. France Head and Neck Squamous Cell Carcinoma Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Type
6.3.1.2.2. By Route of Administration
6.3.1.2.3. By Treatment
6.3.1.2.4. By End-user
6.3.2. Germany Head and Neck Squamous Cell Carcinoma Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Type
6.3.2.2.2. By Route of Administration
6.3.2.2.3. By Treatment
6.3.2.2.4. By End-user
6.3.3. Spain Head and Neck Squamous Cell Carcinoma Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Type
6.3.3.2.2. By Route of Administration
6.3.3.2.3. By Treatment
6.3.3.2.4. By End-user
6.3.4. Italy Head and Neck Squamous Cell Carcinoma Market Outlook
6.3.4.1. Market Size & Forecast
6.3.4.1.1. By Value
6.3.4.2. Market Share & Forecast
6.3.4.2.1. By Type
6.3.4.2.2. By Route of Administration
6.3.4.2.3. By Treatment
6.3.4.2.4. By End-user
6.3.5. United Kingdom Head and Neck Squamous Cell Carcinoma Market Outlook
6.3.5.1. Market Size & Forecast
6.3.5.1.1. By Value
6.3.5.2. Market Share & Forecast
6.3.5.2.1. By Type
6.3.5.2.2. By Route of Administration
6.3.5.2.3. By Treatment
6.3.5.2.4. By End-user
7. North America Head and Neck Squamous Cell Carcinoma Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Type
7.2.2. By Route of Administration
7.2.3. By End-user
7.2.4. By Treatment
7.2.5. By Country
7.3. North America: Country Analysis
7.3.1. United States Head and Neck Squamous Cell Carcinoma Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Type
7.3.1.2.2. By Route of Administration
7.3.1.2.3. By Treatment
7.3.1.2.4. By End-user
7.3.2. Mexico Head and Neck Squamous Cell Carcinoma Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Type
7.3.2.2.2. By Route of Administration
7.3.2.2.3. By Treatment
7.3.2.2.4. By End-user
7.3.3. Canada Head and Neck Squamous Cell Carcinoma Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Type
7.3.3.2.2. By Route of Administration
7.3.3.2.3. By Treatment
7.3.3.2.4. By End-user
8. South America Head and Neck Squamous Cell Carcinoma Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Type
8.2.2. By Route of Administration
8.2.3. By End-user
8.2.4. By Treatment
8.2.5. By Country
8.3. South America: Country Analysis
8.3.1. Brazil Head and Neck Squamous Cell Carcinoma Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Type
8.3.1.2.2. By Route of Administration
8.3.1.2.3. By Treatment
8.3.1.2.4. By End-user
8.3.2. Argentina Head and Neck Squamous Cell Carcinoma Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Type
8.3.2.2.2. By Route of Administration
8.3.2.2.3. By Treatment
8.3.2.2.4. By End-user
8.3.3. Colombia Head and Neck Squamous Cell Carcinoma Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Type
8.3.3.2.2. By Route of Administration
8.3.3.2.3. By Treatment
8.3.3.2.4. By End-user
9. Middle East and Africa Head and Neck Squamous Cell Carcinoma Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Type
9.2.2. By Route of Administration
9.2.3. By Treatment
9.2.4. By End-user
9.2.5. By Country
9.3. MEA: Country Analysis
9.3.1. South Africa Head and Neck Squamous Cell Carcinoma Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Type
9.3.1.2.2. By Route of Administration
9.3.1.2.3. By Treatment
9.3.1.2.4. By End-user
9.3.2. Saudi Arabia Head and Neck Squamous Cell Carcinoma Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Type
9.3.2.2.2. By Route of Administration
9.3.2.2.3. By Treatment
9.3.2.2.4. By End-user
9.3.3. UAE Head and Neck Squamous Cell Carcinoma Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Type
9.3.3.2.2. By Route of Administration
9.3.3.2.3. By Treatment
9.3.3.2.4. By End-user
10. Market Dynamics
10.1. Drivers
10.2. Challenges
11. Market Trends & Developments
11.1. Recent Developments
11.2. Product Launches
11.3. Mergers & Acquisitions
12. Global Head and Neck Squamous Cell Carcinoma Market: SWOT Analysis
